CRTX Key Statistics, Chart & Performance
The current stock price of CRTX is 1.95 USD. In the past month the price decreased by -12.16%. In the past year, price decreased by -96.55%.
CRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CRTX
Company Profile
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The company’s pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer, and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. Its drug-targeting platform allows the Company to take small molecules, peptides, or large molecules and deliver them directly to the site of disease or injury. The firm's drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. Its COR588 is a second-generation small-molecule lysine-gingipain inhibitor.
Company Info
CORTEXYME INC
269 East Grand Ave
South San Francisco CALIFORNIA 94080 US
CEO: Casey C. Lynch
Employees: 55
Phone: 14159105717.0
CORTEXYME INC / CRTX FAQ
What does CORTEXYME INC do?
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The company’s pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer, and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. Its drug-targeting platform allows the Company to take small molecules, peptides, or large molecules and deliver them directly to the site of disease or injury. The firm's drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. Its COR588 is a second-generation small-molecule lysine-gingipain inhibitor.
What is the current price of CRTX stock?
The current stock price of CRTX is 1.95 USD. The price increased by 2.63% in the last trading session.
Does CRTX stock pay dividends?
CRTX does not pay a dividend.
How is the ChartMill rating for CORTEXYME INC?
CRTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in CORTEXYME INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRTX.
What is the ownership structure of CORTEXYME INC (CRTX)?
You can find the ownership structure of CORTEXYME INC (CRTX) on the Ownership tab.
CRTX Technical Analysis
CRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRTX. CRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CRTX Financial Highlights
Over the last trailing twelve months CRTX reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS decreased by -6.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.21% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CRTX Forecast & Estimates
11 analysts have analysed CRTX and the average price target is 22.7 USD. This implies a price increase of 1063.85% is expected in the next year compared to the current price of 1.95.